anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis, a multifaceted syndrome driven by an imbalanced host response to infection, remains a significant medical challenge. At its core lies the pivotal role of glycolysis, orchestrating immune responses especially in severe sepsis. The intertwined dynamics between glycolysis, sepsis, and immunity, however, have gaps in knowledge with several Crucial genes still shrouded in ambiguity. We harvested transcriptomic profiles from the peripheral blood of 107 septic patients juxtaposed against 29 healthy controls. Delving into this dataset, differential expression analysis shed light on genes distinctly linked to glycolysis in both cohorts. Harnessing the prowess of LASSO regression and SVM-RFE, we isolated Crucial genes, paving the way for a sepsis risk prediction model, subsequently vetted via Calibration and decision curve analysis. Using the CIBERSORT algorithm, we further mapped 22 immune cell subtypes within the septic samples, establishing potential interactions with the delineated Crucial genes. Our efforts unveiled 21 genes intricately tied to glycolysis that exhibited differential expression patterns. Gene set enrichment analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses offered insights, spotlighting pathways predominantly associated with oxidative phosphorylation, PPAR signaling pathway, Glycolysis/Gluconeogenesis and HIF-1 signaling pathway. Among the myriad genes, IER3, DSC2, and PPARG emerged as linchpins, their prominence in sepsis further validated through ROC analytics. These sentinel genes demonstrated profound affiliations with various immune cell facets, bridging the complex terrain of glycolysis, sepsis, and immune responses. In line with our endeavor to "unveil the glycolysis in sepsis," the discovery of IER3, DSC2, and PPARG reinforces their cardinal roles in sepsis pathogenesis. These revelations accentuate the intricate dance between glycolysis and immunological shifts in septic conditions, offering novel avenues for therapeutic interventions.
Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
Aim: The aim of this study, evaluating the effects of different simulation methods (virtual reality assisted simulation, high reality simulation, low reality simulation) used in Adult Basic Life Support (BLS) training on knowledge, skills, self-efficacy and satisfaction characteristics in Layperson First Aider Material and Method: The population of the research consists of participants in the TYD and OED (Automatic External Defibrillator) training with participation certificate to be given to public institutions by the Ministry of Health in Ankara between 01.01.2024 and 10.03.2024. Power analysis was performed using the G\*Power (v3.1.9) program to determine the sample size. The medium effect size (d=0.45) used in a previous similar study was calculated at the end of the study as. Type I error α=0.05, Study power 1-β (β=Type II error probability) 0.8, and 3 groups were calculated by means of a statistical power analysis. The estimated total sample size of all intervention groups was 51. Considering that there may be losses during the study process, it was decided to recruit 20 people in each group.This study was designed as a prospective randomized controlled trial. As data collection tools: Introductory Characteristics Form, General Self-Efficacy Scale (GAS), Basic Life Support Knowledge Level Evaluation Form, Basic Life Support Application Skill Form, Basic Life Support Self-Efficacy Questionnaire and Basic Life Support Education Satisfaction Questionnaire were used.
Eligible participants from LAI116482 (NCT01641809 \[LATTE\]) study who were administered oral CAB 30 milligrams (mg) plus RPV 25 mg and who successfully completed Week 300 received their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections were administered 1 month after initial loading dose, with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants continued to receive the treatment until the study intervention was locally approved and commercially available. Participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason entered a 52-week long-term follow-up (LTFU) Phase.
Photodynamic therapy (PDT) is an experimental treatment that uses a drug called a photosensitizer or photosensitizing agent and light to kill cells. When photosensitizers are exposed to a specific wavelength of light, they produce a form of oxygen that kills hearby cells. The appeal o PDT in oncology has been that the photosensitizer is retained in tumor tissue for longer periods of time compared to normal tissues. This reported differential of photosensitizer retention in tumor compared to normal tissues provides the potential for an enhanced therapeutic index minimizing normal tissue toxicity has prompted an interest in studying PDT as a cancer treatment and is a proposed treatment for a variety of malignancies and pre-malignant conditions. The proposed study is a Phase I trial of photodynamic therapy (PDT) for the treatment of patients with pleural malignancies. To participate patients must be 18 years of age or older, must have a histological diagnosis of pleural malignancy, must have disease limited to the hemithorax (one side of the chest), must be medically suitable for resection, and must have a ECOG performance status of 0-2. Patients who have received prior surgery, gene therapy, or combination chemotherapy will also be permitted if it has been at least 30 days since the last treatment. Patients will be given HPPH, by intravenous injection prior to surgery. HPPH is a chlorine based photosensitizer used along with PDT to prevent recurrence of tumors following surgical removal. After successful tumor removal light from a tunable dye laser or diode laser will be administered. The starting dose of PDT will ve administered 24 or 48 hours prior to surgical resection. Red light will be used to illuminate the entire thoracic cavity. If adequate removal of the tumor cannot be performed , the patient will not be eligible to receive light therapy. In parallel laboratory studies, biopsies of tumor and normal tissues will be taken from the resection specimens. Uptake of HPPH will be measured in tumor and normal tissues and tumor to normal tissue ratios of HPPH will be determined. Assessment of molecular signaling including EGFR, Akt, and MAPK will be made in tumor prior to and after light delivery. Patients will simultaneously be enrolled on a companion protocol in which the 2-nitroimidazole, EF5 will be administered to determine tumor oxygen concentration. Finally, non-invasive measurements of optical properties, tissue oxygenation, photosensitizer uptake, and blood flow will be made intraoperatively. After hospital discharge patients will be seen routinely in outpatient Thoracic Surgery and Radiation Oncology Department clinics. These follow visits will occur one month., two months later and every three months of the first 24 months to assess treatment related toxicities. A history and physical examination, laboratory and a CT or MRI of the chest will be performed every 3 months. A follow-up chest x-ray will be obtained as clinically indicated. An assessment of toxicity will be made at each follow-up visit. After 24 months, follow-up should be scheduled as clinically indicated.
Fibrosis has been characterized as a global health problem and ranks as one of the primary causes of organ dysfunction. Currently, there is no cure for pulmonary fibrosis, and limited therapeutic options are available due to an inadequate understanding of the disease pathogenesis. The absence of advanced in vitro models replicating dynamic temporal changes observed in the tissue with the progression of the disease is a significant impediment in the development of novel antifibrotic treatments, which has motivated research on tissue-mimetic three-dimensional (3D) models. In this review, we summarize emerging trends in preparing advanced lung models to recapitulate biochemical and biomechanical processes associated with lung fibrogenesis. We begin by describing the importance of in vivo studies and highlighting the often poor correlation between preclinical research and clinical outcomes and the limitations of conventional cell culture in accurately simulating the 3D tissue microenvironment. Rapid advancement in biomaterials, biofabrication, biomicrofluidics, and related bioengineering techniques are enabling the preparation of in vitro models to reproduce the epithelium structure and operate as reliable drug screening strategies for precise prediction. Improving and understanding these model systems is necessary to find the cross-talks between growing cells and the stage at which myofibroblasts differentiate. These advanced models allow us to utilize the knowledge and identify, characterize, and hand pick medicines beneficial to the human community. The challenges of the current approaches, along with the opportunities for further research with potential for translation in this field, are presented toward developing novel treatments for pulmonary fibrosis.
This study aimed to analyze perioperative results in robot-assisted laparoscopic urological surgeries, comparing the AirSeal system with traditional pneumoperitoneum systems. This study adhered to the PRISMA guidelines for conducting systematic reviews and meta-analyses. Extensive searches were conducted in PubMed, EMBASE, and Google Scholar, including randomized controlled trials (RCTs) and cohort studies up to June 15, 2024. A combined examination of the studies found that the AirSeal system had superior results in terms of surgery duration, end-tidal carbon dioxide levels, and tidal volume compared to the traditional pneumoperitoneum system. During robotic-assisted partial nephrectomy, the AirSeal team experienced a notable decrease in surgical time, ETCO2, and VT. In addition, the occurrence of SCE was lower in the AirSeal group. However, there were no significant differences observed between the groups regarding EBL, LOHS, overall complications, and major complications. Compared to conventional pneumoperitoneum systems, the AirSeal system offers several advantages in robot-assisted laparoscopic urological surgery: reduced operative time, lower end-tidal CO2 pressure, and decreased tidal volume. Furthermore, implementing the AirSeal system does not lead to higher rates of complications, estimated blood loss, or lengthier hospital stays.
The disclosure discloses Lactobacillus sp. BB1 enhancing memory ability, a fermented food and application thereof, and belongs to the technical field of microorganisms. The Lactobacillus sp. BB1 disclosed by the disclosure can be used for preparing functional foods, health-care products and drugs that enhance the memory ability of a healthy individual and improve memory impairment. The disclosure further provides the fermented food. The fermented food is prepared by fermentation with Lactobacillus sp. BB1, comprises a solid food, a liquid food and a semisolid food, and has a wide application prospect.
Supplement formulations of estrogen blocker, glycogen manager, and muscle recovery solutions and sublingual therapies for increasing absorption rates thereof. The sublingual delivery systems allow the body to absorb up to 94.9% of each dose directly into the bloodstream, completely bypassing the digestion process. Sublingual delivery (under the tongue) results in potencies 4 to 5 times greater than most capsules and powders. An estrogen blocker solution includes purified water, vegetable glycerin, polypropylene glycol, potassium benzoate, citric acid, calcium D glucarate, 7 keto DHEA, IO3, DIM, nettle root extract, agaricus biporus extract, narigin extract, and quercetin dehydrate. Formulas for glycogen manager, and muscle recovery are also disclosed. The glycogen manager formula includes the effective ingredients phellodendron extract, Banaba extract, Vanadium, and Chromium. A method of use involves taking one or two droppers (1 or 2 ml) of the solution sublingually for 30 seconds, and then swallowing.
Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
The hydrolysate is one having a Dextrose Equivalent (D.E.) of 35, pref. 5-25, spec. 9-13, and pref. one having a descriptive ratio of >=2, the descriptive ratio being the quotient obtd. by dividing the sum of the percentages of saccharide, dry baiss, having a degree of polymerisation of 1-6 by the D.E. One way of applying the hydrolysate is by dusting it as a dry powder over the wound, which may for example be a second or third degree burn, stasis ulcer, trophic lesion severe cut or abrasion. The film acts like a natural wound scab and has antibacterial as well as protective properties.
The instant application describes a method for delivering to a user a biometric display containing a graphic representation of the user that communicates health related information about the user. The method includes steps of receiving via a communication network information associated with physical characteristics of the user and health related information associated with the user and generating a biometric display of the user based on the received physical characteristics associated with the user. The biometric display represents a virtual persona of the user tailored toward the received physical characteristics associated with the user. The method also includes steps of generating health parameters based on the received health related information associated with the user and associating the health parameters with their respective body parts on the biometric display. The health parameters communicate to the user health related information regarding their respective body part on the biometric display. The method also includes a step of delivering to the user via the communication network the biometric display along with the associative health parameters.
Process for preparing ferruginous mineral water, esp.for bottling, by stabilising non-flocculated, fresh ferruginous water, having the iron in the ferrous state by addn. of reducing agent, which is pref. ascorbic acid, sodium or magnesium ascorbate or an ascorbyl ester. Pref. the ascorbic acid is added quantities 2.5-6.5, esp.5-6, times the wt. of the ferrous ions. Quantity of ferrous ions is generally 15-20 mg/l and quantity of ascorbic acid 50-100 mg/l. Mineral water contg. stabilised ferrous iron suitable for therapeutic use in anaemia treatment for children and adults. Water is drunk in quantities of 250-500 cc per day and avoids anaemia, weakness, toxicity problems etc. Water may be administered in other forms e.g. in baby foods, by i.v. injection etc.
PURPOSE: A lignan compound separated from Magnoliae flos is provided, which is useful in manufacturing platelet-activating factor and preventing and treating inflammatory diseases. And its manufacturing method is also provided. CONSTITUTION: The method for separating compounds of the formula (1) and (2) is comprised of the next steps of: i) mashing 3kg of Magnoliae flos and obtaining extracts using methanol; ii) condensing the extracts; iii) suspending the extracts in distilled water and obtaining ethylacetate; iv) obtaining the two compounds from ethylacetate by silica gel column chromatography. The compound of the formula (1) has no color, and molecular weight of 402. And its molecular formula is C22H26O7. The compound of the formula (2) has no color and molecular weight of 432 and its molecular formula is C23H28O8.
Pulmonary arterial hypertension (PAH) is a complex disease characterized by elevated pulmonary vascular resistance, resulting in right ventricular (RV) hypertrophy and, eventually, failure, which remains the primary cause of mortality in PAH patients. While current PAH therapies primarily target vascular abnormalities, most fail to address RV dysfunction. Therefore, improving RV function is a critical treatment goal. Exercise has emerged as an effective intervention for PAH, but the specific impact of swimming exercise on this disease and its associated pathological changes has been less extensively studied. In this study, we investigated the effects of swimming training (60 min/day, 5 days/week for 4 weeks) on monocrotaline (MCT; 60 mg/kg, i. p.)-induced PAH in rats. Our findings demonstrate that swimming significantly attenuates RV hypertrophy and reduces mean pulmonary arterial pressure (MPAP), mitigating the detrimental effects of PAH. Furthermore, we observed structural remodeling in the right ventricle, including increased myocardial necrosis, collagen deposition, and fibrosis-related protein expression. Swimming exercise training was found to reduce these pathological changes, suggesting a protective effect on the right ventricle. Mechanistically, our study revealed the crucial role of meta-inflammation in PAH and the anti-PAH effects of exercise. Swimming training attenuated macrophage accumulation, reduced serum inflammatory cytokines, and improved systemic and RV insulin sensitivity, highlighting its potential to modulate meta-inflammatory processes. In summary, our study suggests that swimming training exerts a beneficial effect on RV function and hypertrophy in MCT-induced PAH rats by targeting meta-inflammation. These results underscore the potential value of exercise-based rehabilitation as a complementary therapy for PAH patients.
The number of primary open angle glaucoma (POAG) cases will increase by 250% by 2050, directly affecting over 7 million lives. These numbers are specifically for POAG and do not include the many who are monitored and treated for elevated intraocular pressure or for glaucoma suspect status, which along with POAG can all be considered glaucoma associated diseases (GAD). Development of high-quality, accessible, and cost-effective strategies for eye care for these individuals is of critical importance. POAG is at least 4-5 times higher in African Americans, progresses more rapidly and appears about 10 years earlier as compared to those of European descent. This research plan seeks to implement and evaluate a telemedicine-based detection and management strategy for GAD and other eye diseases in patients seen at Federally Qualified Health Centers (FQHC's) located in the rural Alabama Black Belt Region. This region is characterized by one of the highest concentrations of African Americans in the US; high poverty, unemployment, and uninsured rates; inadequate educational systems, transportation and community resources; few optometrists who largely practice in retail settings; and no ophthalmologists specializing in glaucoma. The investigators have developed and tested a novel multimodal telemedicine approach in a prior Centers for Disease Control and Prevention (CDC) funded Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) study that used comprehensive remote optic nerve assessment (RONA). This proposal will employ a modification of the EQUALITY approach using portable measurement of visual function and optic nerve and retinal structure that are more applicable to rural locations with limited resources. The investigators will also identify and evaluate remediation strategies for the barriers to patient adherence with referral and follow-up appointments by comparing the effectiveness of financial incentives along with a validated patient education program versus a validated patient education program alone. Using this program within FQHC's will enable expansion nationwide into rural and urban underserved locations as these centers provide primary health care services in underserved areas and treat more than 27 million people yearly at over 12,000 sites.
FIELD: medicine.SUBSTANCE: group of inventions relates to treatment of type 1 diabetes mellitus (T1D). Proposed is a lactic acid bacterium (LAB) for treating T1D by means of delivery of an interleukin-2 (IL-2) polypeptide and a T1D-specific antigen polypeptide into the mucosa, wherein said LAB comprises an exogenous nucleic acid encoding said IL-2 polypeptide and an exogenous nucleic acid encoding said T1D-specific antigen polypeptide. Said LAB is therein capable of producing said IL-2 polypeptide and said T1D-specific antigen polypeptide. Said T1D-specific antigen polypeptide therein constitutes: proinsulin (PINS), glutamic acid decarboxylase (GAD65), insulinoma-associated protein 2 (IA-2), a catalytic subunit of a bound protein of islet-specific glucose-6-phosphatase (IGRP), a zinc transporter 8 (ZnT8), chromogranin A, a (prepro)islet amyloid polypeptide (ppIAPP), peripherin or a citrullinated glucose-regulated protein (GRP). Also proposed is a composition for treating T1D by delivery of an IL-2 polypeptide and a T1D-specific antigen polypeptide into the mucosa, containing, in an effective amount, (a) a first LAB containing an exogenous nucleic acid encoding said IL-2 polypeptide and capable of producing said IL-2 polypeptide, and (b) a second LAB containing an exogenous nucleic acid encoding said T1D-specific antigen polypeptide and capable of producing said T1D-specific antigen polypeptide. Said LAB or composition are used as part of a pharmaceutical composition and also applied in a method for treating T1D in a mammalian subject in need thereof.EFFECT: group of inventions ensures stimulation and activation of Treg cells.40 cl, 23 dwg, 5 tbl, 9 ex
Patients undergo hemithoracic radiation therapy. After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
Saccharomyces boulardii Oral Tablet 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
PURPOSE: A pharmaceutical composition containing loganin and pharmaceutically acceptable salt thereof is provided to prevent and treat neurodegenerative diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating neurodegenerative disease contains loganin or pharmaceutically acceptable salt thereof. The composition additionally contains pharmaceutically acceptable carriers. A food composition for treating neurodegenerative diseases contains loganin or pharmaceutically acceptable salt thereof. The neurodegenerative diseases are Parkinson's disease, stress, aging, stroke, or Huntington's disease. The food composition is used in the form of pill, powder, granule, tablet, capsule, or beverage.
Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3.
Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.

Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.

DRUG/LABORATORY TEST INTERACTIONS 

As a result of the presence of nitrofurantoin, a false-positive reaction for glucose in the urine may occur. This has been observed with Benedict's and Fehling's solutions but not with the glucose enzymatic test.